Rucaparib Camsylate is a novel DNA repair enzyme poly-ADP ribose polymerase-1 (PARP-1) inhibitor.
ChEBI: Rucaparib camsylate is a camphorsulfonate salt obtained by reaction of rucaparib with one molar equivalent of (1S,4R)-camphorsulfonic acid. It is an inhibitor of poly (ADP-ribose) polymerase and is used as monotherapy for advanced ovarian cancer and deleterious germline or somatic BRCA mutation. It has a role as an EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor. It is a camphorsulfonate salt and an azepinoindole. It contains a (S)-camphorsulfonate and a rucaparib(1+).
Rucaparib is an inhibitor of the DNA repair enzyme poly-ADP ribose polymerase-1 (PARP-1). It has been found to have anticancer activity in a number of cancers and has been approved for treatment of previously treated, BRCA-mutant ovarian cancer.
Rucaparib (AG014699) monocamsylate and AG14584 significantly increase Temozolomide toxicity. Rucaparib (1 mg/kg) monocamsylate significantly increases Temozolomide-induced body weight loss. Rucaparib (0.1 mg/kg) monocamsylate results in a 50% increase in the temozolomide-induced tumor growth delay[1].
Rucaparib (10 mg/kg for i.p. or 50, 150 mg/kg for p.o.; daily for 5 days per week for 6 weeks) monocamsylate significantly inhibits the growth of the tumor, and there is one complete tumor regression and two persistent partial regressions[2].
Rucaparib (150 mg/kg; p.o.; once per week for 6 weeks or three times per week for 6 weeks) monocamsylate has greatest antitumor effect with three complete regressions[2].
Rucaparib monocamsylate enhances the antitumor activity of temozolomide and indicates complete and sustained tumor regression in NB1691 and SHSY5Y xenografts[6].
| Animal Model: | Female CD-1 nude mice aged 10-12 weeks with Capan-1 cells[2] |
| Dosage: | 10mg/kg or 50, 150 mg/kg |
| Administration: | 10mg/kg for i.p. or 50, 150 mg/kg for p.o. |
| Result: | Significantly inhibited the growth of the tumor.
|
PARP-1: 1.4 nM (Ki); PARP-2; PARP-3
